Literature DB >> 21878845

Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization.

Jane Zea-Chin Kuo1, Frank Shih-Chang Ong, Ling Yeung, Wei-Chi Wu, Yen-Po Chen, Nan-Kai Wang, Chi-Chun Lai.   

Abstract

PURPOSE: To report the anatomical and functional outcomes of intravitreal bevacizumab in both young and old Chinese patients with myopic choroidal neovascularization.
METHODS: Consecutive series of 56 eyes (52 patients) with myopic choroidal neovascularization treated exclusively with intravitreal bevacizumab were reviewed retrospectively. Data from clinical examination, fundus photography, fluorescein angiography, and optical coherence tomography were collected.
RESULTS: Vision significantly improved after intravitreal bevacizumab in this patient series (P < 0.0001), with an average of 2.2 injections. Higher myopia was positively correlated to a worse outcome (r = -0.3, P = 0.036). Stratifying by age, the correlation between spherical equivalent and final outcome showed statistical significance (r = -0.44, P = 0.027) only in younger patients. In younger patients, both spherical equivalent (P = 0.036) and initial visual acuity (P = 0.004) were predictive factors for visual outcome after adjusting for age, spherical equivalent, and number of injections, whereas in older patients, only initial visual acuity (P < 0.0001) was predictive of visual outcome after similar adjustments.
CONCLUSION: Younger patients do not have a better outcome when compared with older patients. Initial visual acuity, regardless of age, plays a more significant role. Both initial visual acuity and spherical equivalent are predictive factors for final visual acuity in young Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878845      PMCID: PMC3203533          DOI: 10.1097/IAE.0b013e31821ba2dc

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  34 in total

1.  Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.

Authors:  Myriam L Hernández-Rojas; Hugo Quiroz-Mercado; José Dalma-Weiszhausz; Jans Fromow-Guerra; Andrés Amaya-Espinosa; Adriana Solís-Vivanco; Elizabeth Reyna-Castelán; Maura Abraham-Marín; Maria Ana Martínez-Castellanos; Lloyd P Aiello
Journal:  Retina       Date:  2007 Jul-Aug       Impact factor: 4.256

2.  Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome.

Authors:  J M Ruiz-Moreno; P Amat; J A Montero; F Lugo
Journal:  Br J Ophthalmol       Date:  2008-06       Impact factor: 4.638

3.  Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.

Authors:  W-M Chan; T Y Y Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2008-09-18       Impact factor: 4.638

4.  Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.

Authors:  H Sakaguchi; Y Ikuno; F Gomi; M Kamei; M Sawa; M Tsujikawa; Y Oshima; S Kusaka; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-16       Impact factor: 4.638

5.  Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Satoshi Teramukai; Noriaki Shimada; Muka Moriyama; Wakako Hara; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Am J Ophthalmol       Date:  2008-01-22       Impact factor: 5.258

Review 6.  Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment.

Authors:  Gisèle Soubrane
Journal:  Surv Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 6.048

7.  Enzyme-induced posterior vitreous detachment in the rat produces increased lens nuclear pO2 levels.

Authors:  F J Giblin; P A Quiram; V R Leverenz; R M Baker; Loan Dang; M T Trese
Journal:  Exp Eye Res       Date:  2008-09-18       Impact factor: 3.467

Review 8.  Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.

Authors:  L Arias; N Planas; S Prades; J M Caminal; M Rubio; O Pujol; G Roca
Journal:  Br J Ophthalmol       Date:  2008-08       Impact factor: 4.638

9.  Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.

Authors:  Yasushi Ikuno; Kaori Sayanagi; Kaori Soga; Miki Sawa; Motokazu Tsujikawa; Fumi Gomi; Yasuo Tano
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

10.  Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.

Authors:  Magda Gharbiya; Francesca Allievi; Luigi Mazzeo; Corrado Balacco Gabrieli
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

View more
  7 in total

1.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

2.  Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization.

Authors:  Claudio Traversi; Elisabetta Nuti; Davide Marigliani; Gabriele Cevenini; Angelo Balestrazzi; Gianluca Martone; Tomaso Caporossi; Gian Marco Tosi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-13       Impact factor: 3.117

3.  Regression of iris neovascularization after subconjunctival injection of bevacizumab.

Authors:  Na Kyung Ryoo; Eun Ji Lee; Tae-Woo Kim
Journal:  Korean J Ophthalmol       Date:  2013-07-18

4.  Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization.

Authors:  Cherng-Ru Hsu; Tso-Ting Lai; Yi-Ting Hsieh; Tzyy-Chang Ho; Chung-May Yang; Chang-Hao Yang
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

5.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013

6.  Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.

Authors:  Jia-Kang Wang; Tzu-Lun Huang; Pei-Yao Chang; Yen-Ting Chen; Chin-Wei Chang; Fang-Ting Chen; Yung-Ray Hsu; Yun-Ju Chen
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

7.  Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.

Authors:  Robin D Hamilton; Andreas Clemens; Angelo Maria Minnella; Timothy Y Y Lai; Hong Dai; Taiji Sakamoto; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Cornelia Dunger-Baldauf; Frank G Holz
Journal:  PLoS One       Date:  2020-01-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.